An mRNA–LNP platform for hepatic expression of a bispecific IFN-α/anti-GPC3 protein showed significant antitumor activity against GPC3-positive hepatocellular carcinoma by enhancing CD8+ T-cell infiltration and synergizing with anti-PD-1 therapy. The gene discussed is GPC3; the disease is hepatocellular carcinoma.